FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures, a severe form of seizures, in patients 12 years and older. FYCOMPA (perampanel) CIII, which was approved by the FDA in October 2012 and became available in January 2014, is currently indicated as an adjunctive treatment for partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older.

The sNDA was submitted to the FDA on August 19, 2014. Acceptance of the sNDA indicates that the FDA has found the company's submission to be sufficiently complete to review. "Eisai remains dedicated to advancing epilepsy care for patients, and the acceptance of this sNDA represents an important step toward expanding treatment options for patients whose PGTC seizures are not controlled by their current medication," said Lynn Kramer, Chief Clinical Officer, President, Neuroscience & General Medicine PCU Eisai Product Creation Systems, Eisai, Inc.




The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Exploring the link between lifestyle patterns and depression in diabetic individuals